Park Taek Kyu, Chang Sung-A, Yang Jeong Hoon, Kwon Woochan, Kim Min Yeong, Cho Young Seok, Park Hye Yun, Jeong Dong Seop, Kim Hojoong, Kim Duk Kyung
Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Korean Circ J. 2024 Jul;54(7):409-421. doi: 10.4070/kcj.2024.0021. Epub 2024 Jun 3.
The recent developments in chronic thromboembolic pulmonary hypertension (CTEPH) are emphasizing the multidisciplinary team. We report on the changes in clinical practice following the development of a multidisciplinary team, based on our 7 years of experience.
Multidisciplinary team was established in 2015 offering both balloon pulmonary angioplasty (BPA) and pulmonary endarterectomy (PEA) with technical upgrades by internal and external expertise. For operable cases, PEA was recommended as the primary treatment modality, followed by pulmonary angiography and right heart catheterization after 6 months to evaluate treatment effect and identify patients requiring further BPA. For patients with inoperable anatomy or high surgical risk, BPA was recommended as the initial treatment modality. Patient data and clinical outcomes were closely monitored.
The number of CTEPH treatments rapidly increased and postoperative survival improved after team development. Before the team, 38 patients were treated by PEA for 18 years; however, 125 patients were treated by PEA or BPA after the team for 7 years. The number of PEA performed was 64 and that of BPA 342 sessions. World Health Organization functional class I or II was achieved in 93% of patients. The patients treated with PEA was younger, male dominant, higher pulmonary artery pressure, and smaller cardiac index, than BPA-only patients. In-hospital death after PEA was only 1 case and none after BPA.
The balanced development of BPA and PEA through a multidisciplinary team approach proved synergistic in increasing the number of actively treated CTEPH patients and improving clinical outcomes.
慢性血栓栓塞性肺动脉高压(CTEPH)的最新进展凸显了多学科团队的重要性。基于我们7年的经验,我们报告了多学科团队建立后临床实践的变化。
2015年成立了多学科团队,提供球囊肺动脉血管成形术(BPA)和肺动脉内膜剥脱术(PEA),并借助内部和外部专业知识进行技术升级。对于可手术的病例,推荐PEA作为主要治疗方式,术后6个月进行肺动脉造影和右心导管检查以评估治疗效果并确定需要进一步BPA治疗的患者。对于解剖结构不可手术或手术风险高的患者,推荐BPA作为初始治疗方式。密切监测患者数据和临床结局。
团队建立后,CTEPH治疗数量迅速增加,术后生存率提高。在团队建立之前,18年间有38例患者接受了PEA治疗;然而,团队建立后的7年间,有125例患者接受了PEA或BPA治疗。PEA实施例数为64例,BPA为342例。93%的患者达到世界卫生组织功能分级I级或II级。接受PEA治疗的患者比仅接受BPA治疗的患者更年轻、以男性为主、肺动脉压力更高且心脏指数更小。PEA术后院内死亡仅1例,BPA术后无死亡病例。
通过多学科团队方法实现BPA和PEA的平衡发展,在增加积极治疗的CTEPH患者数量和改善临床结局方面显示出协同作用。